BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
about
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaRegulation of mitochondrial functions by protein phosphorylation and dephosphorylationHsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsCrystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound stateOne more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment.Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapyAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroApplication of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaAlternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit.Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.New dosing schedules of dasatinib for CML and adverse event managementBleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell linesBosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.Emerging drugs for chronic myeloid leukemia.Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesGlobal phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.The anti-apoptotic form of tyrosine kinase Lyn that is generated by proteolysis is degraded by the N-end rule pathway.A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphomaFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.Chronic myeloid leukemia: mechanisms of blastic transformationAssociation between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.
P2860
Q24299821-E8AED393-FAB2-4364-ABC5-1F86450F4D2DQ24605527-7A03B15C-65E4-4099-BEEB-77C09B1461F6Q26752880-299842CD-9467-49E2-8AB6-1C7D593E9449Q26771790-5C848A62-9A1C-4818-B97D-0A89DBA23A0CQ26828528-D1F169A8-7671-484B-A978-411ACD394085Q27025242-FF1EAD90-648A-4AB7-9A50-FB988442FC89Q27028181-FC28C9C7-E429-48B9-9549-513B46399EBAQ27652762-AA047D54-E10D-4CDE-8CE1-1D090AAE61D5Q27692583-DCAA6E81-DB1A-4A82-9D9F-6D4F7E3C7025Q27851450-2D067A3E-BB4E-4279-856A-2683D4D9208DQ28477131-E8DDE29D-9B71-4A4E-9B44-9B380AD5AA18Q28477903-7053C16B-CF10-44C5-9548-2069C6A40F98Q28534259-E56E9C2A-0FF9-44D7-BC6F-2CE7AC57A771Q30156952-7CE264ED-96E0-45E9-BB62-54FA09AA6F2AQ30159676-68D5DD80-621F-4B2B-B27E-517E97541C34Q30374671-2FBD7115-973D-4DEF-A394-BE2F6D121566Q30981853-85C235DF-0661-45F4-8B7B-BCC3AEECBBACQ33383407-2D99428E-A5A9-4300-BE04-2C64330640CAQ33383664-DF938A1D-6FA7-4B64-9466-107E25D9E5AAQ33384766-72C1A779-21B1-4BC7-95C9-AFB591C66D52Q33394772-E12BA886-E45A-4923-85A1-B80A98959801Q33409151-49087BA1-1908-4348-8128-D68AF237E32AQ33442587-C878EDE0-DBA2-4F09-B400-C2AAF82E077CQ33466143-A415A2FA-3943-48B1-928F-67A498AD15CAQ33482818-9300F971-0844-4D3C-9CFA-24EC51E217A2Q33536762-FCAC292E-C7E9-4719-93A1-F650D03916C1Q33561227-BFB641E0-2539-4CEF-9071-C371BF3D9410Q33730375-6871E09B-5EC8-4027-9790-B5F5C50BF679Q33753325-8A220052-5A7C-4B3A-9F8E-7A6EA637F10FQ33757090-0B837A08-3A1F-4DD4-A14B-EEA654453A96Q33767209-DFCD641F-1D18-4B12-BE4F-7CBBF0A96E60Q33770326-5C102A77-1C0A-4D9F-AB12-E433A7214F3FQ33822130-A105E1F6-A24C-476B-8EAA-E40A62354D36Q33843477-4863BC6D-B1FC-4E5A-BF7D-306A1754E169Q33911230-0FC8CB25-100F-441A-89BC-7FE599435604Q33927591-81A085D0-6921-4A0C-9921-8B12F34A4980Q33967180-B4E5184D-13CE-4ABC-B727-347DEAD757A0Q33968037-2BA5DB2D-2390-412C-8973-F5D75EE3021DQ33988398-652F5E4B-8ED7-4942-8D20-8D463CC88270Q34004994-598105AA-3612-4969-80EB-4732DA2C5C51
P2860
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
BCR-ABL independence and LYN k ...... cted for resistance to STI571.
@en
BCR-ABL independence and LYN k ...... cted for resistance to STI571.
@nl
type
label
BCR-ABL independence and LYN k ...... cted for resistance to STI571.
@en
BCR-ABL independence and LYN k ...... cted for resistance to STI571.
@nl
prefLabel
BCR-ABL independence and LYN k ...... cted for resistance to STI571.
@en
BCR-ABL independence and LYN k ...... cted for resistance to STI571.
@nl
P2093
P356
P1433
P1476
BCR-ABL independence and LYN k ...... cted for resistance to STI571.
@en
P2093
Gary Gallick
Ji Yuan Wu
Jonathan Stapley
Moshe Talpaz
Nicholas J Donato
Ralph Arlinghaus
P304
P356
10.1182/BLOOD.V101.2.690
P407
P577
2003-01-01T00:00:00Z